{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:26:44Z","timestamp":1787898404936,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>In China, hepatorenal syndrome is a serious complication in the decompensated stage of hepatitis B cirrhosis, which requires early clinical intervention, so the early diagnosis of hepatorenal syndrome is crucial. This study establishes a new predictive model based on serum biomarkers for the early diagnosis of hepatorenal syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with decompensated hepatitis B cirrhosis who met the inclusion and exclusion criteria were retrospectively enrolled. Patients were randomly assigned to the training dataset and validation dataset at a 7:3 ratio. Univariate and multivariate logistic regression analyses were used to screen the risk factors for hepatorenal syndrome. The identified risk factors were used to establish and verify a model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 255 patients with decompensated hepatitis B cirrhosis, including 184 in the training group and 71 in the validation group. The multivariate logistic regression model was established in the training group and verified in the validation group. Logistic regression showed that hemoglobin (OR 0.938, 95% CI 0.908\u20130.969), total bilirubin (OR 1.014, 95% CI 1.008\u20131.021) and creatinine (OR 1.079, 95% CI 1.043\u20131.117) were independent risk factors for hepatorenal syndrome (P\u2009&lt;\u20090.05). These were used to establish the model. In the training group and the validation group, the area under the ROC curve of the nomogram for the diagnosis of hepatorenal syndrome was 0.968 and 0.980, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The three serum biomarkers, including hemoglobin, total bilirubin and creatinine, can be used as independent early predictors of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-022-02618-x","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T09:03:50Z","timestamp":1672650230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Shouhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhewen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingdi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"issue":"2","key":"2618_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cgh.2017.05.041","volume":"16","author":"AL Mindikoglu","year":"2018","unstructured":"Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018;16(2):162-77.e161.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2618_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531\u20137.","journal-title":"Gut"},{"issue":"4","key":"2618_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","volume":"71","author":"P Angeli","year":"2019","unstructured":"Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811\u201322.","journal-title":"J Hepatol"},{"issue":"13","key":"2618_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","volume":"361","author":"P Gin\u00e8s","year":"2009","unstructured":"Gin\u00e8s P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279\u201390.","journal-title":"N Engl J Med"},{"issue":"7","key":"2618_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/liv.14037","volume":"39","author":"C Sol\u00e9","year":"2019","unstructured":"Sol\u00e9 C, Sol\u00e0 E, Huelin P, Carol M, Moreira R, Cereijo U, Mas JM, Graupera I, Pose E, Napoleone L, et al. Characterization of inflammatory response in hepatorenal syndrome: relationship with kidney outcome and survival. Liver Int. 2019;39(7):1246\u201355.","journal-title":"Liver Int"},{"issue":"1","key":"2618_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/gut.2009.180570","volume":"59","author":"A Krag","year":"2010","unstructured":"Krag A, Bendtsen F, Henriksen JH, M\u00f8ller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59(1):105\u201310.","journal-title":"Gut"},{"issue":"5","key":"2618_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1478-3231.2009.02182.x","volume":"30","author":"JM Trawal\u00e9","year":"2010","unstructured":"Trawal\u00e9 JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sall\u00e9e M, Durand F, Valla D, Lebrec D, Moreau R. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int. 2010;30(5):725\u201332.","journal-title":"Liver Int"},{"issue":"1","key":"2618_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2016.22.1.1","volume":"22","author":"R Moreau","year":"2016","unstructured":"Moreau R. Acute-on-chronic liver failure: a new syndrome in cirrhosis. Clin Mol Hepatol. 2016;22(1):1\u20136.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"2618_CR9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/jgh.13002","volume":"30","author":"T Bucsics","year":"2015","unstructured":"Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study. J Gastroenterol Hepatol. 2015;30(11):1657\u201365.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2618_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/hep.20687","volume":"41","author":"C Alessandria","year":"2005","unstructured":"Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jim\u00e9nez W, Arroyo V, Rod\u00e9s J, Gin\u00e8s P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (Baltimore MD). 2005;41(6):1282\u20139.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"2618_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1572-0241.2005.40952.x","volume":"100","author":"A C\u00e1rdenas","year":"2005","unstructured":"C\u00e1rdenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol. 2005;100(2):460\u20137.","journal-title":"Am J Gastroenterol"},{"key":"2618_CR12","doi-asserted-by":"crossref","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, G\u00fclberg V, Sigal S, Bexon AS, Teuber P. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transplant.\u00a02011;17(11):1328\u201332.","DOI":"10.1002\/lt.22395"},{"issue":"11","key":"2618_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/apt.14052","volume":"45","author":"AJ Sanyal","year":"2017","unstructured":"Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45(11):1390\u2013402.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2618_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jhep.2007.02.001","volume":"46","author":"V Arroyo","year":"2007","unstructured":"Arroyo V, Terra C, Gin\u00e8s P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46(5):935\u201346.","journal-title":"J Hepatol"},{"issue":"11","key":"2618_CR15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/gut.2005.065136","volume":"54","author":"MF Yuen","year":"2005","unstructured":"Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, Wong BC, Lai KC, Lai CL. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54(11):1610\u20134.","journal-title":"Gut"},{"key":"2618_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/IDR.S185120","volume":"12","author":"X Wu","year":"2019","unstructured":"Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist. 2019;12:745\u201357.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"2618_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/kjhep.2012.18.1.1","volume":"18","author":"KT Suk","year":"2012","unstructured":"Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18(1):1\u201321.","journal-title":"Korean J Hepatol"},{"issue":"1","key":"2618_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217\u201331.","journal-title":"J Hepatol"},{"issue":"5","key":"2618_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/apt.13912","volume":"45","author":"FJ Gifford","year":"2017","unstructured":"Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45(5):593\u2013603.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2618_CR20","doi-asserted-by":"publisher","first-page":"e0162987","DOI":"10.1371\/journal.pone.0162987","volume":"11","author":"TH Hung","year":"2016","unstructured":"Hung TH, Lay CJ, Tseng CW, Tsai CC, Tsai CC. The effect of renal function impairment on the mortality of cirrhotic patients: a nationwide population-based 3-year follow-up study. PLoS ONE. 2016;11(9):e0162987.","journal-title":"PLoS ONE"},{"issue":"4","key":"2618_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.5507\/bp.2015.010","volume":"159","author":"M Janicko","year":"2015","unstructured":"Janicko M, Veseliny E, Senajova G, Jarcuska P. Predictors of hepatorenal syndrome in alcoholic liver cirrhosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech. 2015;159(4):661\u20135.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech"},{"issue":"4","key":"2618_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s12072-011-9266-y","volume":"5","author":"MA Sharawey","year":"2011","unstructured":"Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hep Int. 2011;5(4):927\u201333.","journal-title":"Hep Int"},{"issue":"1","key":"2618_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jgh.14387","volume":"34","author":"TH Kim","year":"2019","unstructured":"Kim TH, Lee HA, Seo YS, Lee YR, Yim SY, Lee YS, Suh SJ, Jung YK, Kim JH, An H, et al. Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetyl-\u03b2-D-glucosaminidase. J Gastroenterol Hepatol. 2019;34(1):234\u201340.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2618_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jhep.2014.02.023","volume":"61","author":"R Barreto","year":"2014","unstructured":"Barreto R, Elia C, Sol\u00e0 E, Moreira R, Ariza X, Rodr\u00edguez E, Graupera I, Alfaro I, Morales-Ruiz M, Poch E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 2014;61(1):35\u201342.","journal-title":"J Hepatol"},{"issue":"1","key":"2618_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.ki.5001527","volume":"70","author":"CR Parikh","year":"2006","unstructured":"Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70(1):199\u2013203.","journal-title":"Kidney Int"},{"issue":"7","key":"2618_CR26","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/j.1600-6143.2006.01352.x","volume":"6","author":"CR Parikh","year":"2006","unstructured":"Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelstein CL, Devarajan P. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6(7):1639\u201345.","journal-title":"Am J Transplant"},{"issue":"2","key":"2618_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/hep.26980","volume":"60","author":"JM Belcher","year":"2014","unstructured":"Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, Coca SG, Garcia-Tsao G, Parikh CR. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (Baltimore MD). 2014;60(2):622\u201332.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"5","key":"2618_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/10408363.2021.1879000","volume":"58","author":"Y Wen","year":"2021","unstructured":"Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury. Crit Rev Clin Lab Sci. 2021;58(5):354\u201368.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"2618_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.dld.2016.11.001","volume":"49","author":"DY Yap","year":"2017","unstructured":"Yap DY, Seto WK, Fung J, Chok SH, Chan SC, Chan GC, Yuen MF, Chan TM. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis. 2017;49(2):202\u20136.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2618_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/MCC.0b013e32833e8412","volume":"16","author":"SM Bagshaw","year":"2010","unstructured":"Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care. 2010;16(6):533\u20139.","journal-title":"Curr Opin Crit Care"},{"issue":"3","key":"2618_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1681\/ASN.2006030221","volume":"18","author":"O Liangos","year":"2007","unstructured":"Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2618_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5152\/tjg.2016.16029","volume":"27","author":"G G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r G, Aky\u0131ld\u0131z M, Keskin M, Solak Y, Gaipov A, B\u0131y\u0131k M, \u00c7if\u00e7i S, Ataseven H, Polat H, Demir A. Is there any potential or additive effect of anemia on hepatorenal syndrome? Turk J Gastroenterol. 2016;27(3):273\u20138.","journal-title":"Turk J Gastroenterol"},{"issue":"7\u20138","key":"2618_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2119\/2008-00006.Legrand","volume":"14","author":"M Legrand","year":"2008","unstructured":"Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med (Cambridge Mass). 2008;14(7\u20138):502\u201316.","journal-title":"Mol Med (Cambridge Mass)"},{"key":"2618_CR34","doi-asserted-by":"crossref","unstructured":"Bizid S, Yacoub H, Mohamed G, Ben Slimane B, Boughoula K, Ben Abdallah H, Bouali R, Abedelli N. Does anemia have a potential effect on type 2 hepatorenal syndrome? Can J Gastroenterol Hepatol. 2020;2020:1134744.","DOI":"10.1155\/2020\/1134744"},{"issue":"3","key":"2618_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/187152510791698398","volume":"8","author":"H Schmid","year":"2010","unstructured":"Schmid H, Schiffl H. Erythropoiesis stimulating agents and anaemia of end-stage renal disease. Cardiovasc Hematol Agents Med Chem. 2010;8(3):164\u201372.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"2","key":"2618_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.atherosclerosis.2014.03.015","volume":"234","author":"M Tanaka","year":"2014","unstructured":"Tanaka M, Fukui M, Okada H, Senmaru T, Asano M, Akabame S, Yamazaki M, Tomiyasu K, Oda Y, Hasegawa G, et al. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis. 2014;234(2):421\u20135.","journal-title":"Atherosclerosis"},{"key":"2618_CR37","doi-asserted-by":"crossref","unstructured":"Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28(1):166\u201372.","DOI":"10.1161\/ATVBAHA.107.153262"},{"issue":"4","key":"2618_CR38","doi-asserted-by":"publisher","first-page":"F778","DOI":"10.1152\/ajprenal.00215.2004","volume":"288","author":"CA Adin","year":"2005","unstructured":"Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Ren Physiol. 2005;288(4):F778\u201384.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"2618_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2003.50016","volume":"124","author":"R Wiesner","year":"2003","unstructured":"Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91\u20136.","journal-title":"Gastroenterology"},{"issue":"1","key":"2618_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jhep.2004.11.002","volume":"42","author":"RB Freeman","year":"2005","unstructured":"Freeman RB. MELD: the holy grail of organ allocation? J Hepatol. 2005;42(1):16\u201320.","journal-title":"J Hepatol"},{"issue":"7","key":"2618_CR41","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1055\/s-0032-1330676","volume":"51","author":"M Jani\u010dko","year":"2013","unstructured":"Jani\u010dko M, Vesel\u00edny E, Abraldes JG, Jar\u010du\u0161ka P. Serum sodium identifies patients with cirrhosis at high risk of hepatorenal syndrome. Z Gastroenterol. 2013;51(7):628\u201334.","journal-title":"Z Gastroenterol"},{"issue":"5","key":"2618_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jhep.2012.06.024","volume":"57","author":"P Angeli","year":"2012","unstructured":"Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol. 2012;57(5):1135\u201340.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02618-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T13:03:34Z","timestamp":1672923814000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02618-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02618-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1673256\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"19 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Zhejiang Provincial People\u2019s Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}